What's Driving Pharmacovigilance Technology Acquisition?

The Value and Validity of Social Media Monitoring in Pharmacovigilance

Depression as a Drug Side-Effect: A Quick FAERS Analysis

Can Modern Analytics be Forced into Traditional Pharmacovigilance Workflow Tools?

Advera Health's Commitment to FAERS Data Quality and Turn Around Time

Social Media Monitoring for Pharmacovigilance and Drug Safety

2018- The Year of Next Gen Drug Safety and Pharmacovigilance 2.0

Top Free Drug Safety Downloads of 2017

Most Popular Drug Safety Articles of 2017

Analysis of a FDA Safety Signal: DPP-4's and Rhabdomyolysis

Evidex Goes Global - VigiBase Drug Safety Data Access

An Analysis of Adverse Events Associated with Endothelin Receptor Antagonists (ERAs) using FAERS

Santa Rosa Wildfires - A Very Tough Week at Advera Health

FAERS Thee Well - Drug Safety Excitement with FDA Dashboard

Dear FDA, There is No Single Truth Standard

How Pharmacovigilance Departments Can Work Smarter, Act Bigger

Case Studies: Signal Detection Utilizing FDA Adverse Event Reporting System (FAERS) Data

What happens when a Safety Signal contradicts Clinical Trial data?

FDA Releases Q1 2017 Drug Safety Watch List: It’s Boring and That’s Good

Canada’s March Toward Mandatory Reporting of Adverse Events by Providers

Happy (Drug Safety Data) Independence Day

Failure to Warn: The Week in Drug Safety News

How is Evidex Different from Traditional Signal Detection Software?

Post-Marketing Drug Safety and Pharmacovigilance Is Now More Important Than Ever

Pharmacovigilance 2.0 – Let Freedom Ring in Philadelphia!

2016 FDA Adverse Event Reporting System (FAERS) Data: An Infographic

Evidex Alerts After 3 Months: What We’ve Learned

Using FAERS to Determine Medical Costs – a Payer Perspective

Calculating the Reporting Rate of Adverse Events in FAERS – A New Methodology

Efficacy vs. Effectiveness - The Role of Pharmacovigilance

ICER Underestimates Adverse Event Rates and Costs for Multiple Sclerosis Medications

Make Hair Great Again - The Real Reason for FDA Reform

A Big Data Stumble in Healthcare

Increasing Pressure for Increased Pharmacovgilance Capabilities

Using FAERS Data and Clinical Evidence to Compare HER2+ Antagonists

Drug Safety Progressives – The Rise of the Pharmacovigilante

Advera Health Partners with APCER Life Sciences to Connect Drug Safety to Health Outcomes

Real-Time Drug Safety Analysis with Evidex Alerts

Will 2017 Be The Year of Drug Safety?

Working Toward a Cure: The Foundation for Sarcoidosis Research

Top 10 Free Report Downloads of 2016

Top 10 Advera Health Blog Posts of 2016

Looking Ahead - Drug Safety in 2017

How Memorial Hermann Uses an Evidence Aggregation Platform

Mitigating Drug Litigation Risk with an Evidence Aggregation Platform

Use Clinical Trial Results Linked to Real World Data for Better Formulary Reviews

When Things Go Right in Healthcare

A Drug Safety Data Point That No One Knows About

Establish Adverse Event Benchmarks with a Drug Safety Data Aggregation Platform

Why Does Adverse Event Reporting to FAERS Continue to Accelerate?

Uncover Hidden Data Points with a Drug Safety Data Aggregation Platform

How HEOR Can Demonstrate Cost Burden of Drug Adverse Events

Monitoring Biosimilars with a Drug Safety Data Aggregation Platform

HHS Says they are Finally Going to Enforce Clinical Trial Reporting. Will Anything Really Change?

Construct More Accurate Drug Forecasts using Clinical Trial Results and Real World Data

Seeing the Competitive Landscape with Clinical Trial Results Linked to Real World Data

Drug Safety Snail Mail. Really?

What is a Drug Safety Data Aggregation Platform?

The Drug Pricing Battle Wages On

How Information on Health Care’s Value is Currently Shared

Express Scripts’ 2017 Exclusions – Analysis Using Real World Data

Summer Slowdown? No, Summer Build!

Safety Score & Cost Burden Analysis Update – Which Drugs have Riskiest Profiles?

Guest Post: BBK Talks #BigData with Advera Health Analytics

Chronic Underreporting of Clinical Trials

Honest Salespeople Aren’t Dead

How to Make Sense of the ADA Conference Data Deluge

The Circus is in Town

Nothing is a Waste of Time

3 Reasons a Clinical Evidence Database for Multiple Sclerosis is Important

Playing the Long Game

The Comparative Safety of Multiple Sclerosis Medications – A 2016 Update

Show Me The Evidence!!!

Connect with Advera Health at the AMCP 2016 Annual Meeting

Payers Need Better Access to Clinical Trial Results Prior to Drug Approval

FDA’s Early Warning System is Broken

How Far We’ve Come

Evidex Use Case: Analysis of DPP-4 Inhibitors

How Will You Review All 60 drugs up for Approval in 2016?

A Crystal Ball for FDA Action: How we Validated RxSignal

Watson Health is the Ultimate Data Parasite

In Defense of Millennials

5 Steps to Forming a Consensus to Mitigate Adverse Events

A Quest for Evidence

Fear of Lost Privacy Costs Lives

The Long Run

It’s Confirmed: FDA is Failing When it Comes to Drug Safety

#JPM16 Talks Drug Pricing – Bad Idea!

Big Data, Technology, and the New Health Economy

Data Is Everything… Or Is It? Why Data Management Matters

Top 10 Free Report Downloads of 2015

Top 10 RxView Blog Posts of 2015

Mad as Hell and Not Going to Take This Anymore

Could Diabetes Patients’ Safety Been Improved if the SGLT2 – Ketoacidosis Link Were Known Sooner?

JMCP Validates the Ability to Quantify the Safety Risk of Drugs

Lack of Transparency is Disturbing, Unsurprising, and Validating

FDA is Slow so We FOIA

The Viekira Pak Effect – Will it Change P&T Practices for Good?

To Dare Is To Do

Abbvie’s Viekira Pak Costs $6.5 Million a Year in Avoidable Costs, Puts Patients at Greater Risk

#Rxpocalypse Now

Missing the Boat on the Drug Pricing Argument

The Right Data, Analytics And Measurements

What’s In a Name….Introducing Advera Health Analytics

RxSignal 3.0 - Predicting FDA Label Changes

The FDA Is Approving Everything – Is that Safe?

Choosing the Right Real World Drug Data

CVS Exclusion Decision May Put Patients at Risk on Diabetes Drug (SGLT-2’s)

Did Express Scripts Just Save the Healthcare System an Additional $107.8 Million?

Why is Everyone So Surprised about FDA Side Effect Reporting Delays?

900,000 Side Effect Reports That You Have Never Seen

The State of Drug Safety Systems

Drug Safety Advocate Call to Action

Let YOUR Voice Be Heard on Healthcare Improvement

It Is Time For A Change

When Opportunity Knocks, Open the Door

The Best Thing to Happen to Drug Safety (and it’s Free if you are Qualified)

Define Performance -- Pay-for-Performance Deals Can’t Leave Drug Safety Out

Predicting the Future? Yes, we can.

Shadow Pricing, Highway Robbery, and the Price of Drugs

A New Era of Drug Safety

The Non-Negotiable Cost of Drugs

Blame Canada

Drug Safety Bandits

Trimming The Fat Off Of Post-Marketing Drug Safety

The Cost of Drug Safety

Monitoring the Safety of Biosimilars by Managed Care Organizations: A Practical Approach

An Indecent (Drug Safety) Proposal

Pharma’s Gonna Hate, and We Just Shake it Off

Drug Safety Perspectives on Hepatitis C

RxOutcome – A New Paradigm in Drug Safety

A Drug Safety Call to Arms

Will 2015 Really Be the Year of Healthcare Technology?

Hepatitis C Payer Scorecard: According to Peers, Express Scripts DID Make the Wrong Decision

Did Express Scripts Choose the Right Hepatitis C Drug?

Express Scripts and CVS Exclusivity Deals: Immediate Cost Savings Overshadow Long-Term Medical Concerns

10 Free Report Downloads to Start off the New Year!

2014: The year of data minions, drug safety hipsters, and scarface

Holy @#*!, I Didn’t Know that Drug Safety Data was Available!

3 Ways to Increase Adverse Event Reporting

Is the Status Quo Killing Healthcare?

Should Adverse Drug Event Reporting by Healthcare Providers be Mandatory?

Musings from 38,000 Feet

Data, Disproportionality, & Drug Safety Communications

Moneyball for Drug Safety

Chantix: Why the Black Box Warning Should Remain

Help! There are too many FDA Label Changes and Boxed Warnings and I Don’t Know Which Ones to Pay Attention To!

FAERS - Myths vs. Realities

3 Drug Safety Pharmacy Hacks to Identifying Drug Induced Conditions

Is it Vacation Time Yet?

The Apple iPhone Announcement: It is Only The Second Most Exciting Product Release This Week

How New-Agers and Hipsters are Popularizing Drug Safety

Post Approval Adverse Events... What's the Real World Impact? [INFOGRAPHIC]

Applying Broken Windows Policing Theory to Drug Safety

How Can You Tell When a Lawyer Is Lying?

August: Now The Scariest Month of the Year for Pharma Companies

Quiz: What Type of Drug Safety Professional Are You?

How many links does it take to get to the center of an FDA FOIA request?

OpenFDA – the Good, the Bad, and the Ugly

Why is Questcor’s Disclosure on Acthar Side Effects News?

Drug Safety World Cup: who will win it all?

Drug Safety World Cup: QuarterFinals

Drug Safety World Cup: Time for the Knockout Round!

Did You Know the World Cup has Started?

Hepatitis C: why side effects of treatment are a particularly big deal


3 Ways Drug Safety is Like Car Sales in the 1980’s

Taking A Break from Drug Safety – Honoring our Wounded Warriors this Memorial Day Weekend

From Drug Safety Advocate to Chief Product Officer

My Mother: Mom, Patient Advocate, and now Blogger

What does the FDA and Scarface Have in Common? They Both Understand Power

Fun Challenges

4 Conclusions on the Comparative Safety of Diabetes Drugs

A Framework for Comparable Drug Safety Research

The Big Reveal

FDA Releases Updated Drug Safety Data – Announces OpenFDA… Now hold your applause

Broad Research Study Published in DRUG SAFETY Refutes the ‘Weber Effect'

Qsymia and Belviq Obesity Drugs: When 'Approach Them Cautiously' Just Does Not Cut It

Herd Mentality

Logic. Math. Software. Drug Safety?

Highly Educated and Underutilized: Pharmacists Need to Be More Involved in Drug Safety

Does Brilinta Really Have a Better Drug Safety Profile Than Plavix?

Changing of the Guard - Redefining Drug Safety by Making Big Data Actionable & Predictable

5 Ways Pharmacists Can Better Communicate with Prescribers

Reported Drug Side Effects Have Resulted in 1.1 Million Hospitalizations

Happy New Year!

Wall Street Journal Puts "Me-Too" Drugs in Spotlight

Where Do Doctors Get Their Safety Information?

Why Are We Prescribing the ADHD Medications with the Most Dangerous Safety Profiles?

Did One Little Sentence Just Change Drug Safety Forever?

How Are Post-Approval Adverse Drug Event Data Obtained?

Howard Stern and a “Crappy” Patient Questionnaire

The Disconnect Between Clinical Trials and Real-World Side Effects

The FDA Should Look Closer at These 5 Drugs

The Myth of Alert Fatigue... Some Alerts Just Aren't Actionable!

Imagine a world where drug safety decisions could be made before a FDA Safety Alert

Did Express Scripts Make the Right Formulary Exclusions?

Why is Express Scripts Decision to Remove Drugs From Its Formulary News?

The New York Times Misses The Mark on High Cost of Asthma Inhalers

Patient Engagement, Innovation, and ROI

Can Psychotic Side Effects be Triggered by the Drugs My Child is Taking for ADHD?

3 More Philadelphia Eagle Lessons for Healthcare Leadership

When the FDA approves a drug, that means it is safe, right?

I’m Not Only the Executive Vice President of AdverseEvents, I’m Also a Patient

In The Beginning…FDA Created a Data Nightmare

5 Lessons Drug Safety Can Learn from the NFL

Evidence Based Medicine Without Access to All of the Evidence

Without ROI, Big Data in Healthcare is Doomed